Aggressive B-cell lymphomas gain MYC and BCL2 alterations through mechanisms other than gene translocations, and 18–44% of DLBCLs have been reported to express MYC and BCL2 concurrently [10,11,12,13,14]. Here, BCL2 is linked to B-cell non-Hodgkin lymphoma.